Last reviewed · How we verify
MC2-01 cream
MC2-01 cream is a Topical corticosteroid Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Inflammatory skin conditions (specific indication not publicly detailed). Also known as: Calcipotriol + Betamethasone dipropionate cream.
MC2-01 cream is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied to affected skin areas.
MC2-01 cream is a topical corticosteroid formulation designed to reduce inflammation and provide therapeutic benefit when applied to affected skin areas. Used for Inflammatory skin conditions (specific indication not publicly detailed).
At a glance
| Generic name | MC2-01 cream |
|---|---|
| Also known as | Calcipotriol + Betamethasone dipropionate cream |
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a topical corticosteroid cream, MC2-01 works by binding to glucocorticoid receptors in skin cells, suppressing inflammatory cytokine production and immune cell infiltration. This reduces erythema, pruritus, and other inflammatory manifestations of dermatological conditions. The cream formulation allows for localized delivery to affected areas while minimizing systemic absorption.
Approved indications
- Inflammatory skin conditions (specific indication not publicly detailed)
Common side effects
- Local skin irritation
- Skin atrophy
- Contact dermatitis
Key clinical trials
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream (PHASE3)
- A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects (PHASE2)
- This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream (PHASE3)
- Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream (PHASE1)
- Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream (PHASE1)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MC2-01 cream CI brief — competitive landscape report
- MC2-01 cream updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about MC2-01 cream
What is MC2-01 cream?
How does MC2-01 cream work?
What is MC2-01 cream used for?
Who makes MC2-01 cream?
Is MC2-01 cream also known as anything else?
What drug class is MC2-01 cream in?
What development phase is MC2-01 cream in?
What are the side effects of MC2-01 cream?
What does MC2-01 cream target?
Related
- Drug class: All Topical corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Inflammatory skin conditions (specific indication not publicly detailed)
- Also known as: Calcipotriol + Betamethasone dipropionate cream
- Compare: MC2-01 cream vs similar drugs
- Pricing: MC2-01 cream cost, discount & access